Fotemustine, teniposide and dexamethasone in treating patients with CNS lymphoma

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 11, 2014, Pages 4733-4738

  Wu, Jing Jing ^a   Wang, Xin Hua ^a   Li, Ling ^a   Li, Xin ^a   Zhang, Lei ^a   Sun, Zhen Chang ^a   Fu, Xiao Rui ^a   Ma, Wang ^a   Chang, Yu ^a   Zhang, Xu Dong ^a   Han, Li Juan ^a   Zhang, Ming Zhi ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Central nervous system; Chemotherapy; Lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DEXAMETHASONE; FOTEMUSTINE; METHOTREXATE; NITROSOUREA DERIVATIVE; ORGANOPHOSPHORUS COMPOUND; TENIPOSIDE;

ADJUVANT THERAPY; ADOLESCENT; ADULT; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMPARATIVE STUDY; FEMALE; HUMAN; LYMPHOMA; MALE; MIDDLE AGED; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CYTARABINE; DEXAMETHASONE; FEMALE; HUMANS; LYMPHOMA; MALE; METHOTREXATE; MIDDLE AGED; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; RADIOTHERAPY, ADJUVANT; TENIPOSIDE; YOUNG ADULT;

EID: 84903748639     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.11.4733     Document Type: Article

References (37)

1. Abrey L, DeAngelis LE (2005). CNS lymphomas. Hematal Oncol Clin North Am, 14, 729-38.
2. Abrey LE, Yahalom J, DeAngelis LM (2000). Treatment for primary CNS lymphoma: the next step. J Clin Oncol, 18, 3144-50.
3. Andrés J. M. Ferreri (2011). How I treat primary CNS lymphoma. Blood, 118, 510-22.
4. Batchelor T, Carson K, O'Neill A, et al (2003). Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol, 21, 1044-9.
5. Bierman P, Giglio P (2005). Diagnosis and treatment of central nervous system involvement in non-Hodgkin's lymphoma. Hematol Oncol Clin North Am, 19, 597-609.
6. Boehme V, Zeynalova S, Kloess M, et al (2007). Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol, 18, 149-57.
7. Boehme V, Schmitz N, Zeynalova S, et al (2009). CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood, 113, 3896-902.
8. Chen TE (2006). Primary CNS lymphoma. Neurosurg Focus, 5, 21.
9. DeAngelis LM, Seiferheld W, Schold SC, et al (2002). Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol, 20, 4643-8.
10. FerreriAJ, Abrey LE, Blay JY, et al (2003). Summary statement on primary central nervous system lymphomas from the eighth international conference on malignant lymphoma, J Clin Oncol, 21, 2407-14.
11. FerreriAJ, ReniM, ZoldanMC, et al (1996). Importance of complete staging in nonhodgkin's lymphoma presenting as a cerebral mass lesion. Cancer, 77, 827-33.
12. FerreriAJ, Blay JY, Reni M, et al (2003). Prognostic scoring system for primary CNS lymphomas: the international extranodal lymphoma study group experience. J Clin Oncol, 21, 266-72.
13. G Vassal, I Boland, M J Terrier-Lacombe, et al (1998). Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity. Clin Cancer Res, 4, 463-8.
14. Hoang-Xuan K, Taillandier L, Chinot O, et al (2003). Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol, 21, 2726-31.
15. Jellinger KA, Paulus W (1992). Primary central nervous system lymphomas:An update. J Cancer Res Clin Oncol, 119, 7-27.
16. Jin J, Cai L, Liu ZM, et al (2013). miRNA-218 inhibits osteosarcoma cell migration and invasion by down-regulating of TIAM1, MMP2 and MMP9. Asian Pac J Cancer Prev, 14, 3681-4.
17. Korfel A (2011). Prevention of central nervous system relapses in diffuse large B-cell lymphoma: which patients and how? Curr Opin Oncol, 23, 436-40.
18. Li Q, Yin J, Wang X, et al (2013). B-cell Lymphoma 2 rs17757541 C> G polymorphism was associated with an increased risk of gastric cardiac adenocarcinoma in a Chinese population. Asian Pac J Cancer Prev, 14, 4301-6.
19. Li LF, Wang HQ, Liu XM, et al (2013). Epirubicin inhibits soluble CD25 secretion by Treg cells isolated from diffuse large B-cell lymphoma patients. Asian Pac J Cancer Prev, 14, 1721-4.
20. McAllister LD, Doolittle ND, Guastadisegni PE, et al (2000). Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery, 46, 51-60.
21. Mead GM, Bleehen NM, Gregor A, et al (2000). Amedical research council randomized trial in patients with primary cerebral nonhodgkin lymphoma:cerebral radiotherapy with and without cyclophos-phamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer, 89, 1359-70.
22. Miller DC, Hochberg FH, Harris NL, et al (1994). Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. The Massachusetts General Hospital experience 1958-1989. Cancer, 74, 1383-97.
23. Muggia FM (1994). Teniposide: overview of its therapeutic potential in adult cancers. Cancer Chemother Pharmacol, 34, S127-33.
24. National Cancer Institute (1988): Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute.
25. OBrien P, Roos D, Pratt G, et al (2000) . Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol, 18, 519.
26. Omuro AM, Taillandier L, Chinot O et al (2007), Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol, 85, 207-11.
27. Pels H, Schmidt-Wolf IG, Glasmacher A, et al (2003). Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol, 21, 4489-95.
28. Reni M, Ferreri AJ, Garancini MP, et al (1997). Therapeutic management of primary central nervous system lymphoma in immunocompetent patients:Results of a critical review of the literature. Ann Oncol, 8, 227-34.
29. Rubenstein J, FerreriAJ, Pittaluga S et al (2008). Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. Leuk Lymphoma, 49, 43-51.
30. Sutcliffe SB, Gospodarowicz MK, Bush RS, et al (1985). Role of radiation therapy in localized non-Hodgkin's lymphoma. Radiother Oncol, 4, 211-23.
31. Van Besien K, Ha CS, Murphy S, et al (1998). Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood, 91, 1178-84.
32. Van Tellingen O, Boogerd W, Nooijen WJ, et al (1997). The vascular compartment hampers accurate determination of teniposide penetration into brain tumor tissue. Cancer Chemother Pharmacol, 40, 330-4.
33. Wang X, Song ZF, Xie RM, et al (2013). Analysis of death causes of in-patients with malignant tumors in Sichuan Cancer Hospital of China from 2002 to 2012. Asian Pac J Cancer Prev, 14, 4399-402.
34. Wang XF, Wu YH, Wang MS, et al (2014). CEA, AFP, CA125, CA153 and CA199 in malignant pleural effusions predict the cause. Asian Pac J Cancer Prev, 15, 363-8.
35. Zhu WW, Kang L, Gao YP, et al (2013). Expression level of valosin containing protein is associated with prognosis of primary orbital MALT lymphoma. Asian Pac J Cancer Prev, 14, 6439-43.
36. Zhang J, Zhu MY, Wang L, et al (2013). "Sandwich" chemotherapy (CT) with radiotherapy (RT) improves outcomes in patients with stage IE/IIE extranodal natural killer (NK)/T-cell Lymphomas. Asian Pac J Cancer Prev, 14, 4061-6.
37. Zhang ZX, Shen CF, Zou WH, et al (2013). Exploration of molecular mechanisms of diffuse large B-cell lymphoma development using a microarray. Asian Pac J Cancer Prev, 14, 1731-5.